載入中
NASDAQHealthcareMedical - Diagnostics & Research
最新資料
US$619.21
+US$7.155 · +1.17%
Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance. Medpace's services include designing development programs, coordinating central laboratory functions, managing projects, navigating regulatory processes, overseeing clinical trials, handling data management and analytics, ensuring pharmacovigilance, aiding with new drug application submissions, and providing ongoing post-marketing clinical support. Furthermore, the company offers specialized bio-analytical laboratory testing, conducts clinical human pharmacology studies, provides imaging services, and delivers expert electrocardiography (ECG) reading for clinical research.
一般交易時段
US$619.21
+US$7.155 · +1.17%
盤中時間採用ET。市場資料可能有所延遲。
Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance. Medpace's services include designing development programs, coordinating central laboratory functions, managing projects, navigating regulatory processes, overseeing clinical trials, handling data management and analytics, ensuring pharmacovigilance, aiding with new drug application submissions, and providing ongoing post-marketing clinical support. Furthermore, the company offers specialized bio-analytical laboratory testing, conducts clinical human pharmacology studies, provides imaging services, and delivers expert electrocardiography (ECG) reading for clinical research.
日內區間
目前US$619.21
52週區間
目前US$619.21
盤中時間採用ET。市場資料可能有所延遲。
Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance. Medpace's services include designing development programs, coordinating central laboratory functions, managing projects, navigating regulatory processes, overseeing clinical trials, handling data management and analytics, ensuring pharmacovigilance, aiding with new drug application submissions, and providing ongoing post-marketing clinical support. Furthermore, the company offers specialized bio-analytical laboratory testing, conducts clinical human pharmacology studies, provides imaging services, and delivers expert electrocardiography (ECG) reading for clinical research.
日內區間
目前US$619.21
52週區間
目前US$619.21
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 25.3億 USD | 21.09億 USD | 18.86億 USD | 14.6億 USD | 11.42億 USD |
| 銷貨成本 | 17.7億 USD | 14.53億 USD | 13.61億 USD | 10.28億 USD | 8.14億 USD |
| 毛利 | 7.61億 USD | 6.56億 USD | 5.25億 USD | 4.32億 USD | 3.28億 USD |
| 銷售、一般及管理費用 | 1.98億 USD | 1.8億 USD | 1.61億 USD | 1.31億 USD | 1.08億 USD |
| 營業費用 | 2.26億 USD | 2.09億 USD | 1.88億 USD | 1.54億 USD | 1.3億 USD |
| 利息收入 | — | 2499.6萬 USD | — | — | — |
| 利息支出 | — | — | 48.8萬 USD | 290.5萬 USD | 10.5萬 USD |
| 折舊和攤銷 | 2812.4萬 USD | 2925.1萬 USD | 2632.8萬 USD | 2234.1萬 USD | 2111.9萬 USD |
| 營業利益 | 5.35億 USD | 4.47億 USD | 3.37億 USD | 2.79億 USD | 1.99億 USD |
| 淨利 | 4.51億 USD | 4.04億 USD | 2.83億 USD | 2.45億 USD | 1.82億 USD |
公司資料更新於 2026年10月12日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI4.31億0.02%2.3兆 USD0.03%US$381.42-0.14%
Vanguard Morningstar Small-Cap ETFVB3.12億0.17%1853億 USD0.03%US$288.11-0.47%
Invesco S&P MidCap Quality ETFXMHQ2億3.68%54.37億 USD0.30%US$114.31+0.07%
Vanguard Morningstar Small-Cap Growth ETFVBK1.79億0.39%447億 USD0.05%US$340.65-1.19%
Vanguard Extended Market ETFVXF1.56億0.16%954億 USD0.05%US$233.36-0.70%
iShares Biotechnology ETFIBB1.07億0.99%108.2億 USD0.44%US$204.1-1.16%
State Street SPDR S&P MIDCAP 400 ETF TrustMDY1.03億0.40%258.17億 USD0.23%US$667.38-0.37%
iShares Russell Mid-Cap Growth ETFIWP7771.32萬0.39%200.95億 USD0.23%US$140.88-1.55%Vanguard Morningstar Total Stock Market ETFVTIVanguard Morningstar Small-Cap ETFVBInvesco S&P MidCap Quality ETFXMHQVanguard Morningstar Small-Cap Growth ETFVBKVanguard Extended Market ETFVXFiShares Biotechnology ETFIBBState Street SPDR S&P MIDCAP 400 ETF TrustMDYiShares Russell Mid-Cap Growth ETFIWPAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
